Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 15:2018:5253623.
doi: 10.1155/2018/5253623. eCollection 2018.

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Pajaree Sriuttha  1 , Buntitabhon Sirichanchuen  1 , Unchalee Permsuwan  1
Affiliations
Review

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Pajaree Sriuttha et al. Int J Hepatol. .

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain.

Aim of the review: To systematically review published literature on randomized, controlled trials that assessed the risk of clinically significant hepatotoxicity associated with NSAIDs.

Methods: Searches of bibliographic databases EMBASE, PubMed, and the Cochrane Library were conducted up to July 30, 2016, to identify randomized controlled trials of ibuprofen, naproxen, diclofenac, piroxicam, meloxicam, mefenamic acid, indomethacin, celecoxib, and etoricoxib in adults with any disease that provide information on hepatotoxicity outcomes.

Results: Among the 698 studies, 18 studies met the selection criteria. However, only 8 studies regarding three NSAIDs (celecoxib, etoricoxib, and diclofenac) demonstrated clinically significant hepatotoxic evidence based on hepatotoxicity justification criteria. Of all the hepatotoxicity events found from the above-mentioned three NSAIDs, diclofenac had the highest proportion, which ranged from 0.015 to 4.3 (×10-2), followed by celecoxib, which ranged from 0.13 to 0.38 (×10-2), and etoricoxib, which ranged from 0.005 to 0.930 (×10-2).

Conclusion: Diclofenac had higher rates of hepatotoxic evidence compared to other NSAIDs. Hepatotoxic evidence is mostly demonstrated as aminotransferase elevation, while liver-related hospitalization or discontinuation was very low.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The flowchart of the selected studies in this systematic review.
Figure 2
Figure 2
Proportion of hepatotoxicity induced by NSAIDs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ornbjerg L. M., Andersen H. B., Kryger P., Cleal B. What do patients in rheumatologic care know about the risks of NSAIDs? J Clin Rheumatol: practical reports on rheumatic & musculoskeletal diseases. 2008;14(2):69–73. - PubMed
    1. Shah S., Mehta V. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management. Postgraduate Medical Journal. 2012;88(1036):73–78. doi: 10.1136/postgradmedj-2011-130291. - DOI - PubMed
    1. Zhou Y., Boudreau D. M., Freedman A. N. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiology and Drug Safety. 2014;23(1):43–50. doi: 10.1002/pds.3463. - DOI - PubMed
    1. Health Product Vigilance Center, Food and Drug Administration, Adverse Events data from 1984, 2016, http://thaihpvc.fda.moph.go.ththaihvcpublic/News/uploads/hpvc_5_13_0_100....
    1. Sarges P., Steinberg J. M., Lewis J. H. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Safety. 2016;39(9):801–821. doi: 10.1007/s40264-016-0427-8. - DOI - PubMed

LinkOut - more resources